Abstract: An Industrial Internet of Things system for managing a production task is provided. The system comprises a user platform, a service platform, a management platform, a sensor network platform interacted sequentially. The service platform is configured to receive a modification instruction of a user. The management platform is configured to obtain raw material data and reference material data; determine target reference material data whose matching relationship satisfies a preset condition, and take reference process parameters corresponding to the target reference material data as first candidate process parameters; determining second candidate process parameters through processing the first candidate process parameters; and determine target process parameters based on cost values corresponding to the second candidate process parameters; and determine a modification plan.

Abstract: The embodiments of the present disclosure provide a method for obtaining a natural gas energy metering component, including obtaining a temperature and pressure of a natural gas sample to be detected at a first site based on an object platform; obtaining sample data of a natural gas sample at a second site based on the object platform, the sample data including a natural gas component and a temperature and pressure of the natural gas component; obtaining sample data of a natural gas sample at the first site based on the object platform; determining a natural gas component of the natural gas sample to be detected at the first site based on sample data at the first site and the second site aggregated by a sensor network platform and the temperature and pressure of the natural gas sample to be detected at the first site.

Abstract: The embodiments of the present disclosure provide methods and systems for energy measuring based on natural gas data of a smart gas meter, including establishing the gas IoT. The object platform obtains consumed gas volume data and location data of the smart gas meter as first data and second data, and sending them to the management platform through the sensor network platform. The management platform generates consumed gas preprocessing data based on the first data and the second data, and generates energy measurement data after performing the computation outside the gas IoT on the consumed gas preprocessing data by the cloud platform outside the gas IoT. The management platform sends the energy measurement data to the user platform configured in a regional pipeline network center through the service platform. The user platform performs gas energy measurement of the smart gas meter based on the energy measurement data.

Abstract: An industrial internet of things system for intelligent production control is provided, comprising: a user platform, a service platform, a management platform, a sensor network platform, and an object platform. The user platform modifies production line parameters based on an instruction of the user, generates a first instruction, and sends it to the management platform through the transformation of the service platform. The object platform collects production link data of each production link of products and transmits it to the management platform. The management platform modifies work order parameters based on a second instruction transformed by the service platform, generates a third instruction, and determines whether devices corresponding to the plurality of production links are abnormal based on the production link data.

Abstract: The present disclosure provides a method for smart gas pipeline transportation performance prediction. The method includes: determining, based on a gas pipeline map, transportation performance of a target gas pipeline section by a transportation performance determination model, wherein the gas pipeline map reflects a connection relationship of a plurality of gas pipeline sections within a preset range of the target gas pipeline section, and the gas pipeline map is generated based on information of one or more historical gas pipeline sections; nodes of the gas pipeline map include connections between the gas pipeline sections, gas storage points, gate stations, or pipeline bends, and edges of the gas pipeline map include the gas pipeline sections; a node feature of the gas pipeline map includes whether to process gas, an edge feature of the gas pipeline map includes pipeline parameters and a pipeline maintenance situation.

Abstract: The disclosure relates to synthetic oligonucleotides that bind at least a portion of a dimerization initiation site (DIS) of a retrovirus genomic ribonucleic acid (RNA) molecule. In some aspects, the synthetic oligonucleotides include a 2?-deoxy-2?-fluoroarabinonucleotide (2?-FANA)-modified nucleotide sequence. In some embodiments, the 2?-FANA-modified nucleotide sequence inhibits dimerization of retroviral genomes (e.g., an HIV genome). Other embodiments include methods of inhibiting expression of a retrovirus using the synthetic oligonucleotide, and methods of treating or preventing a retroviral infection.

Abstract: The present invention relates to novel Collagen 1 translation inhibitors, composition and methods of preparation thereof, and uses thereof for treating Fibrosis including lung, liver, kidney, cardiac and dermal fibrosis, IPF, wound healing, scarring and Gingival fibromatosis, Systemic Sclerosis, and alcoholic and non-alcoholic steatohepatitis (NASH).

Abstract: The present invention relates to novel c-MYC mRNA translation modulators, composition and methods of preparation thereof, and uses thereof in the treatment of cancer.

Abstract: The disclosure relates to synthetic oligonucleotides that bind at least a portion of a dimerization initiation site (DIS) of a retrovirus genomic ribonucleic acid (RNA) molecule. In some aspects, the synthetic oligonucleotides include a 2-deoxy-2-fluoroarabinonucleotide (2-FANA)-modified nucleotide sequence. In some embodiments, the 2-FANA-modified nucleotide sequence inhibits dimerization of retroviral genomes (e.g., an HIV genome). Other embodiments include methods of inhibiting expression of a retrovirus using the synthetic oligonucleotide, and methods of treating or preventing a retroviral infection.

Abstract: The present invention is directed to pyrimidine carboxamide compounds of formula I which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 2 (PDE2). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis, Parkinson's disease, Parkinson's disease dementia (PDD), or Huntington's disease, and those associated with striatal hypofunction or basal ganglia dysfunction.

Abstract: The present invention is directed to 6-alkyl dihydropyrazolopyrimidinone compounds of formula (I) which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 2 (PDE2). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis, Parkinson's disease, Parkinson's disease dementia (PDD), or Huntington's disease, and those associated with striatal hypo-function or basal ganglia dysfunction.

Abstract: The present invention is directed to pyrimidine carboxamide compounds of formula I which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 2 (PDE2). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis, Parkinson's disease, Parkinson's disease dementia (PDD), or Huntington's disease, and those associated with striatal hypofunction or basal ganglia dysfunction.

Abstract: The present invention is directed to 6-alkyl dihydropyrazolopyrimidinone compounds of formula (I) which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 2 (PDE2). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis, Parkinson's disease, Parkinson's disease dementia (PDD), or Huntington's disease, and those associated with striatal hypo-function or basal ganglia dysfunction.